As part of the acquisition, Sequenom has formalized certain collaborative agreements with Spectrum Health and the Van Andel Research Institute, which were joint venture partners in the Clinical Laboratory Improvement Act (CLIA) laboratory. The CLIA laboratory has been renamed to the Sequenom Center for Molecular Medicine.
Harry Stylli, president and CEO of Sequenom, said: “This acquisition is a major step in our SEQureDx strategy as it provides us with control over all aspects of commercialization. In addition to a CLIA-certified facility, we gain the expertise from Spectrum Health in marketing and in developing critical sales and third-party payer reimbursement contracting strategies.”